JERUSALEM, June 9, 2016 /PRNewswire/ --
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP)
(http://www.oramed.com), a clinical-stage pharmaceutical company
focused on the development of oral drug delivery systems, announced
today that a scientific abstract summarizing a study performed in
animals with its orally ingestible insulin capsule, ORMD-0801, will
be presented in a poster at the ADA 76th Scientific
Sessions on June 11-13, 2016 in New Orleans.
The poster was also selected to be included in a moderated
tour of select posters.
The American Diabetes
Association 76th Scientific
Sessions
Poster title: "Pharmacokinetic and Pharmacodynamic
Profiles of Orally, Duodenally and Subcutaneously Delivered Insulin
in Beagle Canines"
Date: June 11-13, 2016
Location: The Ernest N. Morial Convention Center in
New Orleans
About the American Diabetes
Association (ADA) Scientific
Sessions
The American Diabetes Association's Scientific Sessions offers
researchers and health care professionals from around the world the
unique opportunity to share ideas and learn about the significant
advances in diabetes research, treatment, and care. Some 16,000
people are expected to attend.
http://professional.diabetes.org/meeting/scientific-sessions/76th-scientific-sessions
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a platform technology pioneer in the
field of oral delivery solutions for drugs currently delivered via
injection. Established in 2006, Oramed's Protein Oral Delivery
(PODTM) technology is based on over 30 years of research
by scientists at Jerusalem's
Hadassah Medical Center. Oramed is seeking to revolutionize the
treatment of diabetes through its proprietary flagship product, an
orally ingestible insulin capsule (ORMD-0801). The Company
completed multiple Phase II clinical trials under an
Investigational New Drug application with the U.S. Food and Drug
Administration. In addition, Oramed is developing an oral GLP-1
analog capsule (ORMD-0901).
For more information, the content of which is not part of
this press release, please visit
http://www.oramed.com
Forward-looking statements: This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 and other federal
securities laws. Words such as "expects," "anticipates," "intends,"
"plans," "believes," "seeks," "estimates" and similar expressions
or variations of such words are intended to identify
forward-looking statements. For example, we are using
forward-looking statements when we discuss our studies and
development or when we discuss revolutionizing the treatment of
diabetes with our products. These forward-looking statements are
based on the current expectations of the management of Oramed only,
and are subject to a number of factors and uncertainties that could
cause actual results to differ materially from those described in
the forward-looking statements, including the risks and
uncertainties related to the progress, timing, cost, and results of
clinical trials and product development programs; difficulties or
delays in obtaining regulatory approval or patent protection for
our product candidates; competition from other pharmaceutical or
biotechnology companies; and our ability to obtain additional
funding required to conduct our research, development and
commercialization activities. In addition, the following factors,
among others, could cause actual results to differ materially from
those described in the forward-looking statements: changes in
technology and market requirements; delays or obstacles in
launching our clinical trials; changes in legislation; inability to
timely develop and introduce new technologies, products and
applications; lack of validation of our technology as we progress
further and lack of acceptance of our methods by the scientific
community; inability to retain or attract key employees whose
knowledge is essential to the development of our products;
unforeseen scientific difficulties that may develop with our
process; greater cost of final product than anticipated; loss of
market share and pressure on pricing resulting from competition;
laboratory results that do not translate to equally good results in
real settings; our patents may not be sufficient; and finally that
products may harm recipients, all of which could cause the actual
results or performance of Oramed to differ materially from those
contemplated in such forward-looking statements. Except as
otherwise required by law, Oramed undertakes no obligation to
publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. For a more detailed
description of the risks and uncertainties affecting Oramed,
reference is made to Oramed's reports filed from time to time with
the Securities and Exchange Commission.
Company Contact
Oramed Pharmaceuticals
Estee Yaari
Office: +972-2-566-0001
US: +1-718-831-2512
Email: estee@oramed.com
SOURCE Oramed Pharmaceuticals Inc.